Cargando…

Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database

OBJECTIVES: To determine the use and expenditure associated with cystic fibrosis (CF) modulator therapies in Ireland since their reimbursement in 2013. DESIGN: A retrospective analysis of a national drug claims database. SETTING: The data included in this study are nationally representative (Ireland...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Amelia, Barry, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668370/
https://www.ncbi.nlm.nih.gov/pubmed/33191267
http://dx.doi.org/10.1136/bmjopen-2020-040806
_version_ 1783610473410723840
author Smith, Amelia
Barry, Michael
author_facet Smith, Amelia
Barry, Michael
author_sort Smith, Amelia
collection PubMed
description OBJECTIVES: To determine the use and expenditure associated with cystic fibrosis (CF) modulator therapies in Ireland since their reimbursement in 2013. DESIGN: A retrospective analysis of a national drug claims database. SETTING: The data included in this study are nationally representative (Ireland). PARTICIPANTS: Data on all persons receiving CF modulator therapies were included. METHODS: We obtained national claims data for CF therapies from the Health Service Executive’s Primary Care Reimbursement Service. We determined the use and expenditure associated with CF therapies from January 2012 to March 2020. RESULTS: The increased prescribing of CF modulator therapies was associated with an approximate fivefold increase in expenditure from €23 million in 2013 to €113 million in 2019. Many patients who initiated lumacaftor/ivacaftor in 2017 went on to receive symptomatic therapies, and subsequently initiated tezacaftor/ivacaftor in 2019. CONCLUSION: Despite none of these modulator therapies demonstrating value for money when subjected to health technology assessment, the associated Irish expenditure reached €113 million in 2019 alone.
format Online
Article
Text
id pubmed-7668370
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-76683702020-11-24 Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database Smith, Amelia Barry, Michael BMJ Open Pharmacology and Therapeutics OBJECTIVES: To determine the use and expenditure associated with cystic fibrosis (CF) modulator therapies in Ireland since their reimbursement in 2013. DESIGN: A retrospective analysis of a national drug claims database. SETTING: The data included in this study are nationally representative (Ireland). PARTICIPANTS: Data on all persons receiving CF modulator therapies were included. METHODS: We obtained national claims data for CF therapies from the Health Service Executive’s Primary Care Reimbursement Service. We determined the use and expenditure associated with CF therapies from January 2012 to March 2020. RESULTS: The increased prescribing of CF modulator therapies was associated with an approximate fivefold increase in expenditure from €23 million in 2013 to €113 million in 2019. Many patients who initiated lumacaftor/ivacaftor in 2017 went on to receive symptomatic therapies, and subsequently initiated tezacaftor/ivacaftor in 2019. CONCLUSION: Despite none of these modulator therapies demonstrating value for money when subjected to health technology assessment, the associated Irish expenditure reached €113 million in 2019 alone. BMJ Publishing Group 2020-11-14 /pmc/articles/PMC7668370/ /pubmed/33191267 http://dx.doi.org/10.1136/bmjopen-2020-040806 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Pharmacology and Therapeutics
Smith, Amelia
Barry, Michael
Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
title Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
title_full Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
title_fullStr Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
title_full_unstemmed Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
title_short Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
title_sort utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in ireland: a retrospective analysis of a national pharmacy claims database
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668370/
https://www.ncbi.nlm.nih.gov/pubmed/33191267
http://dx.doi.org/10.1136/bmjopen-2020-040806
work_keys_str_mv AT smithamelia utilisationexpenditureandcosteffectivenessofcysticfibrosisdrugsinirelandaretrospectiveanalysisofanationalpharmacyclaimsdatabase
AT barrymichael utilisationexpenditureandcosteffectivenessofcysticfibrosisdrugsinirelandaretrospectiveanalysisofanationalpharmacyclaimsdatabase